Origin and physicochemical properties
Low-molecular-weight heparins are produced by depolymerization of conventional (unfractionated) heparin, which is isolated from the porcine intestinal mucosa. This process yields shortened polysaccharide chains.
- Chain length: 17 or fewer saccharide units.
- Molecular weight: from 1,000 to 10,000 Daltons (average 4,000–5,000 Da).
The drugs of this group are heterogeneous. They represent different fractions and therefore differ from each other in composition, molecular weight, and biological activity. For example, the molecular weight of dalteparin sodium is 5,000–6,000 Da, while for nadroparin and reviparin this parameter ranges from 3,900 to 4,500 Da.
Mechanism of action and selectivity
Like standard heparin, LMWHs work by activating antithrombin III. However, the short chain length fundamentally alters drug specificity.
Standard heparin binds both antithrombin III and thrombin (factor IIa) simultaneously. Most LMWH fractions are too short for such dual binding, but their length is quite sufficient for successful inactivation of factor Xa. As a result, LMWHs suppress factor Xa 2–4 times more strongly than thrombin.
The ratio of anti-Xa to anti-thrombin activity is strictly individual for each drug:
- For enoxaparin sodium (Clexane) — 3.8:1.
- For nadroparin (Fraxiparine) and reviparin (Clivarin) — 3.2–3.5:1.
- For dalteparin sodium (Fragmin) — 2.2–2.7:1.
Advantages over standard heparin
Low-molecular-weight fractions bind significantly less to blood plasma proteins, vascular endothelium, and macrophages. This ensures a predictable and stable anticoagulant response.
Key pharmacokinetic differences:
- High bioavailability. With subcutaneous administration, it reaches ≥90%, whereas for standard heparin it does not exceed 30%.
- Duration of action. The drugs work longer, allowing them to be administered just 1–2 times a day.
- Convenience of monitoring. Since the bleeding risk is lower, patients do not require constant laboratory monitoring of blood coagulation (aPTT).
Furthermore, unlike classical heparin, LMWHs practically do not suppress platelet aggregation. At the same time, they effectively stimulate fibrinolysis by releasing tissue plasminogen activator from the endothelium.
Clinical application
LMWH dosing is carried out in International Units (IU), and the criterion of activity is the degree of factor Xa inhibition. The primary route of administration is subcutaneous, but intravenous use is possible if a rapid effect is required (the result sets in after 5 minutes).
Main indications:
- Prevention and treatment of deep vein thrombosis (especially in the postoperative period).
- Prevention of pulmonary embolism (PE).
- Acute coronary syndrome (myocardial infarction, unstable angina).
LMWHs are of particular importance in obstetric practice. They practically do not cross the placental barrier, making them a safe choice for the fetus when treating and preventing thrombosis in pregnant women.
Important rule: LMWH drugs are strictly not interchangeable. Substituting one agent for another during a course of treatment is not recommended.
Safety profile and adverse effects
LMWH therapy features a high degree of safety, but carries its own risks:
- Bleeding: occurs significantly less frequently than with unfractionated heparin therapy.
- Thrombocytopenia: a mild form is possible in the first few days. Severe immune thrombocytopenia is rare (no more than 1% of cases) because LMWHs form fewer immunogenic complexes with platelet factor 4.
- Other reactions: allergic manifestations and elevated liver transaminase activity may be observed. The risk of osteoporosis is lower than with standard heparin.
In case of overdose, the antidote protamine sulfate is used. It is important to remember that it is less effective against LMWHs. Protamine neutralizes long-chain fragments, which are extremely scarce in low-molecular-weight drugs.
Briefly: answers to topical questions
What are the absolute contraindications to the use of low-molecular-weight heparins?
An absolute contraindication to the use of low-molecular-weight heparins is the development of heparin-induced thrombocytopenia.
Clinical situations precluding standard administration:
- Heparin-induced thrombocytopenia — administration is contraindicated due to the risk of a cross-reaction.
- Pediatric age — currently in Russia, the use of all drugs in this group in children is officially contraindicated (administration is possible exclusively by decision of a medical commission off-label).
In which clinical situations is laboratory monitoring of anti-Xa activity required during LMWH treatment?
Laboratory assessment of anti-Xa activity is used to determine the magnitude of the LMWH effect in hemorrhagic stroke, including to decide on reversal: when anti-Xa levels are ≥ 0.3 and/or an intracerebral hematoma occurs less than 12 hours after the last LMWH administration.
In obese patients, routine dose adjustment of LMWHs guided by anti-Xa activity has not been proven to be beneficial. Individual monitoring in selected patients was previously permitted, and it is assumed that some of them may benefit from it, but the level of evidence for this approach is very low.
NMG — No Monitoring, Greater safety
Class and exam questions
Is it necessary to monitor aPTT when prescribing low-molecular-weight heparins?
No. Due to stable protein binding and a predictable anticoagulant response, routine laboratory coagulation monitoring via aPTT is not required.
Can one LMWH drug be substituted for another during treatment?
This is strictly not recommended. The drugs in the group are heterogeneous; they differ in molecular weight, physicochemical properties, and activity ratio, and therefore are not interchangeable.
Are these anticoagulants safe during pregnancy?
Yes, they are widely used in obstetric practice because they practically do not cross the placental barrier and are absolutely safe for the fetus.
What else to study on this topic
- Mechanism of antithrombin III activation and the blood coagulation cascade
- Comparative pharmacokinetics of unfractionated heparin
- Pathogenesis of heparin-induced thrombocytopenia
- Mechanisms of fibrinolysis and the role of tissue plasminogen activator
Master the entire topic in the «Pharmacology» course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Low-Molecular-Weight Heparins" and 5,304 other subject pages
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 116 video lessons on the subject
Other topics in the section "Drugs affecting hemostasis and thrombosis"
Free video lessons: pharmacologyShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.